NovaBiotics, a leading clinical-stage biotechnology company, today announces that it has further secured the global intellectual property ('IP') position of its lead product, Novexatin® through recent patent grants in the US, EU and other territories worldwide. Novexatin® is a topical treatment for fungal nail infection and NovaBiotics' recent patent grants protect the use of its core peptide technology in this and other related target indications.
The Company's granted and pending IP not only protects the use of the core structure of NovexatinŽ, but of a related family of anti-infective peptides derived from the same technology platform. This is a critical milestone for the Company with key grants for its lead and follow-on products being secured a relatively early stage in their lifecycle.
NovaBiotics' current antifungal product portfolio includes Novexatin® a phase 2b-ready clinical asset and Novamycin®, a candidate treatment for potentially life-threatening blood-stream and deep tissue yeast and mould infections (predominantly Candida).
In addition, NovaBiotics' antibacterial peptide drug candidate, NP432 and novel mucolytic agent NM001 are now at the early proof of efficacy stage for the treatment of respiratory infections including multi-drug resistant forms and those associated with cystic fibrosis.
Dr Deborah O'Neil, Founder, commented: "Recent patent grants in key territories for our expanding product portfolio is an important step in NovaBiotics' development, particularly as we bring our lead product Novexatin® closer to market. This undoubtedly adds significant further value for the interested parties with whom we are in ongoing discussions for Novexatin®."
NovaBiotics' IP portfolio covers eight patent families which consist of more than 50 patents pending and granted worldwide.
NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex® | 16 Sep 2014
Precious Cells Biobank Acquires Stem Cell Technology Leader Pharmacells Group | 25 July 2014
NovaBiotics' Dr Deborah O'Neil Wins Entrepreneur of the Year | 27 June 2014
NovaBiotics Initiates Phase IIa Clinical Study for Lynovex in Cystic Fibrosis | 25 June 2014
NovaBiotics' Dr Deborah O'Neil Named EY Scotland Entrepreneur of 2014 | 20 June 2014
NovaBiotics Initiates Development of Orphan Drug in Cystic Fibrosis | 17 December 2013
Pharmacells to expand following funding boost | 24 September 2013
NovaBiotics Enters into Agreement with Taro | 28 August 2013
First patient dosed at Aberdeen Royal Infirmary in major international study | 29 August 2012
Pharmacells in talks to extend reach overseas | 24 January 2012
New hope in cystic fibrosis fight as Scots patients first to test drug | 2 January 2012
NovaBiotics reveals plans for cystic fibrosis drug after EU grants orphan status | 19 December 2011
Pharmacells stores stem cells for teenager paralysed in car crash | 20 October 2011
NovaBiotics Ltd - Presentation at BIO International 2011, Washington DC | 24 June 2011
Launch of Oristem® | 04 June 2011
GBP in Nexxus newsletter, Spring 2011 | 22 March 2011
Patents granted in key territories as Novexatin® moves closer to further clinical development and commercialisation | 21 February 2011
Unblinded Phase IIa Clinical Trial Data Delivers Excellent Results for Novexatin®, Nova... | 5 July 2010
Successful Completion of Phase IIa clinical trial for Novexatin®, IND filing planned for Phase IIb... | 1 May 2010
NovaBiotics' Dr Deborah O'Neil Wins Entrepreneur of the Year
27th June 2014
NovaBiotics Initiates Development of Orphan Drug in Cystic Fibrosis
17th December 2013
Pharmacells to expand following funding boost
24 September 2013